Drug Patents owned by Santen
1. List of Omlonti drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8648097 | SANTEN | Pyridylaminoacetic acid compound |
Oct, 2029
(6 years from now) | |
| US10774072 | SANTEN | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685986 | SANTEN | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(6 years from now) | |
| US10765750 | SANTEN | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US10179127 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US11197849 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US10702511 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| US9415038 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| USRE48183 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
2. List of Verkazia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8524779 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
| US9956289 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
| US9220694 | SANTEN | Emulsion compositions containing cetalkonium chloride |
Jan, 2026
(2 years from now) | |
| US7973081 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
| US8298568 | SANTEN | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Nov, 2027
(4 years from now) | |
| US9132071 | SANTEN | Compositions containing quaternary ammonium compounds |
Jun, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 23, 2028 |
| New Product (NP) | Jun 23, 2023 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 June, 2021
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic